Chek the Channels
TherapeuticsMD Inc. (TXMD)
Q4 2019 Earnings: Annovera is Now the Lead Asset in the Sales Bag
(current) TherapeuticsMD, Inc. is a women's healthcare company focused on developing and commercializing products targeted exclusively for women. It manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins and cosmetics, under our vitaMedMD' and BocaGreenMD' brands. The company is currently developing advanced hormone therapy pharmaceutical products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. It is also evaluating various other potential indications for our hormone technology, including oral contraception, preterm birth, vulvar and vaginal atrophy, and premature ovarian failure.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Annovera sales exceeded expectations and became the lead commercial focus for the company. Annovera reached $5.8 mm in the fourth quarter compared to $0.4 mm in the previous quarter. Total revenue numbers in F2019 exceeded our and street's expectations, mainly attributed to strong Annovera sales. Thus far, the product was soft launched, the full launch is anticipated on March 1st, 2020.
Increasing our F2020 estimates primarily based on Annovera sales. We now forecast $111 mm in revenue compared to $82 mm in 2020, solely based on Annovera sales ($42 mm versus $14 mm previously). We are maintaining our F2021 forecast of $207 mm by lowering Imvexxy/Bijuva and...
This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.